Structural and spectroscopic characterization of the compounds [Al(NMe 2) 3] 2, [Ga(NMe 2) 3] 2, [(Me 2N) 2Al{μ-N(H)1-Ad}] 2 (1-Ad = 1-adamantanyl) and [{Me(μ-NPh 2)Al} 2NPh(μ-C 6H... von Waggoner, K.M., Olmstead, M.M., Power, P.P.

Volltext

InstitutionaI issues which act as barriers to multi-state applications of intelligent transportation systems for commercial vehicle operation von Hancock, M.L., Maze, T.H., Waggoner, K.M.

Volltext bestellen

Self-efficacy, quality of life, and weight loss in overweight/obese endometrial cancer survivors (SUCCEED): A randomized controlled trial von McCarroll, M.L, Armbruster, S, Frasure, H.E, Gothard, M.D, Gil, K.M, Kavanagh, M.B, Waggoner, S, von Gruenigen, V.E

Volltext

The use of novel PP2A activators in combination with PARP inhibitor for the treatment of high-grade serous ovarian cancer von Armstrong, A.J, Joseph, P, Nagaraj, A.B, Nagel, C.I, Nakayama, J, Waggoner, S.E, Zanotti, K.M, DiFeo, A, Narla, G

Volltext

Identifying susceptibilities and pharmacodynamic biomarkers for mirvetuximab soravtansine in high-grade ovarian and endometrial cancer von Hopp, E., Joseph, P., Nakayama, J., Zanotti, K.M., Nagel, C.I., Waggoner, S.E., DiFeo, A.

Volltext

The wnt/β-catenin-specific inhibitor, ICG-001, proves effective for the treatment of high-grade serous ovarian cancer in murine models through the targeting of cancer initiating ce... von Connor, R.S, Nagaraj, A.B, Joseph, P, Mantilla, S, Kovalenko, O, Nagel, C.I, Nakayama, J, Waggoner, S.E, Zanotti, K.M, Singh, S, DiFeo, A

Volltext

Small molecule activators of protein phosphatase 2A for the treatment of endometrial cancer von Joseph, P, Nagaraj, A.B, Armstrong, A, Resnick, K.E, Zanotti, K.M, Waggoner, S.E, Narla, G, DiFeo, A

Volltext

The use of novel PP2A activators in combination withPARP inhibitor for the treatment of high-grade serous ovarian cancer von Armstrong, A.J., Joseph, P., Nagaraj, A.B., Nagel, C.I., Nakayama, J., Waggoner, S.E., Zanotti, K.M., DiFeo, A., Narla, G.

Volltext